Cambios metabólicos de pacientes que reciben algún tipo de tratamiento psicofarmacológico, una revisión sistemática
| datacite.rights | http://purl.org/coar/access_right/c_16ec | spa |
| dc.contributor.advisor | Rivera Porras, Diego Andrés | |
| dc.contributor.advisor | Arenas Villamizar, Vivian Vanesa | |
| dc.contributor.advisor | Bermúdez Pirela, Valmore | |
| dc.contributor.author | Sepulveda Lizcano, Lizeth Natalia | |
| dc.date.accessioned | 2023-05-09T21:08:40Z | |
| dc.date.available | 2023-05-09T21:08:40Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | El tratamiento psicofarmacológico de alteraciones psicopatológicas puede conducir a alteraciones metabólicas que influyen en la salud física y la calidad de vida de los pacientes. El objetivo de esta revisión fue identificar los cambios metabólicos que presentan los pacientes que reciben este tipo de tratamiento, mediante la metodología PRISMA. En las bases de datos SCOPUS, CLARIVATE, SCIENCE DIRECT y PUBMED, seleccionando estudios trasversales, retrospectivos y ensayos clínicos aleatorizados, con antidepresivos, anticonvulsivantes y antipsicóticos, encontrando un total de 64 estudios, donde muestran que la familia de fármacos que mayor riesgo y/o alteraciones metabólicas genera es la de antidepresivos, amitriptilina, Imipramina y clomipramina los cuales provocan en mayor frecuencia aumento de peso, estreñimiento y efectos a nivel cardiovascular. Los antidepresivos ISRS Fluoxetina, Sertralina, Citalopram, Escitalopram, Paroxetina presentan una alta prevalencia de sufrir alteraciones gastro intestinales y alteraciones cardiacas, Los anticonvulsivos acido valproico y Fosfenitoina, generan reacciones adversas como aumento de peso, alteración de apetito y sueño. Los antipsicóticos como Clozapina, Olanzapina, Risperidona, genera aumento de peso, diabetes, deterioro del perfil lipídico. Se concluye que los cambios metabólicos, ocasionados por la medicación psicofarmacológica varía de acuerdo con la edad los sujetos, por tal razón, el seguimiento a los efectos adversos debe realizarse de manera constante, y es pertinente realizar estudios de campo que amplie información relaciona con los demás psicofármacos con prescripción médica más frecuente. | spa |
| dc.description.abstract | Psychopharmacological treatment of psychopathological disorders can lead to metabolic alterations that influence the physical health and quality of life of patients. The aim of this review was to identify the metabolic changes presented by patients receiving this type of treatment, using PRISMA methodology. In the SCOPUS, CLARIVATE, SCIENCE DIRECT and PUBMED databases, selecting cross-sectional, retrospective studies and randomized clinical trials, with antidepressants, anticonvulsants and antipsychotics, we found a total of 64 studies, which show that the family of drugs that generate the greatest risk and/or metabolic alterations are antidepressants, amitriptyline, Imipramine and clomipramine, which most frequently cause weight gain, constipation and cardiovascular effects. The SSRI antidepressants Fluoxetine, Sertraline, Citalopram, Escitalopram, Paroxetine present a high prevalence of gastrointestinal and cardiac alterations. The anticonvulsants valproic acid and Fosphenytoin generate adverse reactions such as weight gain, appetite and sleep alteration. Antipsychotics such as Clozapine, Olanzapine, Risperidone, generate weight gain, diabetes, deterioration of the lipid profile. It is concluded that the metabolic changes caused by psychopharmacological medication vary according to the age of the subjects, for this reason, the monitoring of adverse effects should be carried out constantly, and it is pertinent to carry out field studies that expand information related to the other most frequently prescribed psychotropic drugs. | eng |
| dc.format.mimetype | spa | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/12369 | |
| dc.language.iso | spa | spa |
| dc.publisher | Ediciones Universidad Simón Bolívar | spa |
| dc.publisher | Facultad de Ciencias Jurídicas y Sociales | spa |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.subject | Metabolismo | spa |
| dc.subject | Tratamiento psicofarmacológico | spa |
| dc.subject | Antidepresivos | spa |
| dc.subject | Anticonvulsivos | spa |
| dc.subject | Antipsicóticos | spa |
| dc.subject | Metabolism | eng |
| dc.subject | Psychopharmacological treatment | eng |
| dc.subject | Antidepressants | eng |
| dc.subject | Anticonvulsants | eng |
| dc.subject | Antipsychotics | eng |
| dc.title | Cambios metabólicos de pacientes que reciben algún tipo de tratamiento psicofarmacológico, una revisión sistemática | spa |
| dc.type.driver | info:eu-repo/semantics/masterThesis | spa |
| dc.type.spa | Trabajo de grado máster | spa |
| dcterms.references | Abosi, O., Lopes, S., Schmitz, S., & Fiedorowicz, J. G. (2018). Cardiometabolic effects of psychotropic medications. In Hormone Molecular Biology and Clinical Investigation (Vol. 36, Issue 1). De Gruyter. https://doi.org/10.1515/hmbci-2017-0065 | eng |
| dcterms.references | Ahrens, K. R., DuBois, D. L., Richardson, L. P., Fan, M. Y., & Lozano, P. (2008). Youth in foster care with adult mentors during adolescence have improved adult outcomes. Pediatrics, 121(2). https://doi.org/10.1542/peds.2007-0508 | spa |
| dcterms.references | Alalwan, A. A., Friedman, J., Alfayez, O., & Hartzema, A. (2022). Drug absorption in bariatric surgery patients: A narrative review. In Health Science Reports (Vol. 5, Issue 3). John Wiley and Sons Inc. https://doi.org/10.1002/hsr2.605 | spa |
| dcterms.references | Allison, D. B., Mentore, J. L. E., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999). Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis. In Am J Psychiatry (Vol. 156, Issue 11). | spa |
| dcterms.references | Asbjornsdottir, B., Lauth, B., Fasano, A., Thorsdottir, I., Karlsdottir, I., Gudmundsson, L. S., Gottfredsson, M., Smarason, O., Sigurdardottir, S., Halldorsson, T. I., Marteinsson, V. T., Gudmundsdottir, V., & Birgisdottir, B. E. (2022). Meals, Microbiota and Mental Health in Children and Adolescents (MMM-Study): A protocol for an observational longitudinal case-control study. PLoS ONE, 17(9 September). https://doi.org/10.1371/journal.pone.0273855 | spa |
| dcterms.references | Castillo Hernández, J. L., Cuevas González, M. J., Galiana, M. A., & Romero Hernández, E. Y. (2017). SÍNDROME METABÓLICO, UN PROBLEMA DE SALUD PÚBLICA CON DIFERENTES DEFINICIONES Y CRITERIOS METABOLIC SYNDROME, A PUBLIC HEALTH PROBLEM WITH DIFFERENT DEFINITIONS AND CRITERIA. In Artículo Original (Vol. 7, Issue 2). | spa |
| dcterms.references | Chen, J., Yang, Y., Yu, N., Sun, W., Yang, Y., & Zhao, M. (2022). Relationship between gut microbiome characteristics and the effect of nutritional therapy on glycemic control in pregnant women with gestational diabetes mellitus. PLoS ONE, 17(4 April). https://doi.org/10.1371/journal.pone.0267045 | spa |
| dcterms.references | Ciencia, C., & Médico, E. (2019). El aumento de peso y el cambio metabólico con preditores de la mejoría de síntomas en pacientes con trastorno del espectro esquizofrénia con primer episodio tratados durante 12 meses. https://pubmed.ncbi.nlm.nih.gov/30503765/ | spa |
| dcterms.references | Correll, C. U., Agid, O., Crespo-Facorro, B., de Bartolomeis, A., Fagiolini, A., Seppälä, N., & Howes, O. D. (2022). A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia. CNS Drugs, 36(7), 659–679. https://doi.org/10.1007/s40263-022-00932-2 | spa |
| dcterms.references | Criado, K. K., Sharp, W. G., McCracken, C. E., de Vinck-Baroody, O., Dong, L., Aman, M. G., McDougle, C. J., McCracken, J. T., Eugene Arnold, L., Weitzman, C., Leventhal, J. M., Vitiello, B., & Scahill, L. (2018). Overweight and obese status in children with autism spectrum disorder and disruptive behavior. Autism, 22(4), 450–459. https://doi.org/10.1177/1362361316683888 | spa |
| dcterms.references | Dalvi-Garcia, F., Fonseca, L. L., Vasoncelos, A. T. R., Pereira, C. H., & Voit, E. O. (2021a). A model of dopamine and serotonin-kynurenine metabolism in cortisolemia: Implications for depression. PLoS Computational Biology, 17(5). https://doi.org/10.1371/journal.pcbi.1008956 | spa |
| dcterms.references | Dalvi-Garcia, F., Fonseca, L. L., Vasoncelos, A. T. R., Pereira, C. H., & Voit, E. O. (2021b). A model of dopamine and serotonin-kynurenine metabolism in cortisolemia: Implications for depression. PLoS Computational Biology, 17(5). https://doi.org/10.1371/journal.pcbi.1008956 | eng |
| dcterms.references | de San, H., de Bogotá, J., Septiembre, D. C., Jerónimo, C., Sánchez, V., Pablo, J., Chacón, M., Tovar Cortés, H., De, H., José, S., & September, B. D. (2011). PREVALENCIA DEL SÍNDROME METABÓLICO EN CONSULTA DE MEDICINA INTERNA PREVALENCE OF METABOLIC SYNDROME IN PATIENTS ATTENDING THE INTERNAL MEDICINE OUTPATIENT CLINIC. In Repertorio de Medicina y Cirugía (Vol. 20). | spa |
| dcterms.references | Delacrétaz, A., Glatard, A., Dubath, C., Gholam, M., Gamma, F., von Gunten, A., Conus, P., & Eap, C. B. (2021). Valproate is associated with early decrease of high-density lipoprotein cholesterol levels in the psychiatric population. Basic and Clinical Pharmacology and Toxicology, 129(1), 26–35. https://doi.org/10.1111/bcpt.13580 | eng |
| dcterms.references | Domecq, J. P., Prutsky, G., Leppin, A., Sonbol, M. B., Altayar, O., Undavalli, C., Wang, Z., Elraiyah, T., Brito, J. P., Mauck, K. F., Lababidi, M. H., Prokop, L. J., Asi, N., Wei, J., Fidahussein, S., Montori, V. M., & Murad, M. H. (2015). Drugs commonly associated with weight change: A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, 100(2), 363–370. https://doi.org/10.1210/jc.2014-3421 | eng |
| dcterms.references | Fernández-Aranda, F., Sauchelli, S., Pastor, A., Gonzalez, M. L., de La Torre, R., Granero, R., Jiménez-Murcia, S., Baños, R., Botella, C., Fernández-Real, J. M., Fernández-García, J. C., Frühbeck, G., Gómez-Ambrosi, J., Rodríguez, R., Tinahones, F. J., Arcelus, J., Fagundo, A. B., Agüera, Z., Miró, J., & Casanueva, F. F. (2014). Moderate-vigorous physical activity across body mass index in females: Moderating effect of endocannabinoids and temperament. PLoS ONE, 9(8). https://doi.org/10.1371/journal.pone.0104534 | eng |
| dcterms.references | Ford, T. C., Nibbs, R., & Crewther, D. P. (2017). Glutamate/GABA+ ratio is associated with the psychosocial domain of autistic and schizotypal traits. PLoS ONE, 12(7). https://doi.org/10.1371/journal.pone.0181961 | eng |
| dcterms.references | Frayne, J., Watson, S., Snellen, M., Nguyen, T., & Galbally, M. (2021). The association between mental illness, psychotropic medication use and hypertensive disorders in pregnancy: A multicentre study. Pregnancy Hypertension, 24, 22–26. https://doi.org/10.1016/j.preghy.2021.02.002 | eng |
| dcterms.references | Garmendia Lorena, F. (2020). El síndrome metabólico, ¿artificio o realidad? Anales de La Facultad de Medicina, 81(1). https://doi.org/10.15381/anales.v81i1.17787 | spa |
| dcterms.references | Gerardo Garcia Maldonado. (2003). FÁRMACOS ESTIMULANTES Y PSIQUIATRÍA INFANTIL. Goetz, R. L., & Miller, B. J. (2019). Meta-analysis of ghrelin alterations in schizophrenia: Effects of olanzapine. In Schizophrenia Research (Vol. 206, pp. 21–26). Elsevier B.V. https://doi.org/10.1016/j.schres.2018.11.036 | eng |
| dcterms.references | Gómez-Revuelta, M., Pelayo-Terán, J. M., Juncal-Ruiz, M., Ortiz-García de la Foz, V., Vázquez-Bourgon, J., González-Pinto, A., & Crespo-Facorro, B. (2018). Long-term antipsychotic effectiveness in first episode of psychosis: A 3-year follow-up randomized clinical trial comparing aripiprazole, quetiapine, and ziprasidone. International Journal of Neuropsychopharmacology, 21(12), 1090–1101. https://doi.org/10.1093/ijnp/pyy082 | eng |
| dcterms.references | Gomis, R. (2008). Presentation: The threat of metabolic change. Revista Espanola de Cardiologia Suplementos, 8(C). https://doi.org/10.1016/S1131-3587(08)73548-9 | eng |
| dcterms.references | Graff-Guerrero, A., & Müller, D. J. (2022). The present scoping review synthesizes. | eng |
| dcterms.references | Guerdjikova, A. I., McElroy, S. L., Kotwal, R., Stanford, K., & Keck, P. E. (2007). Psychiatric and metabolic characteristics of childhood versus adult-onset obesity in patients seeking weight management. Eating Behaviors, 8(2), 266–276. https://doi.org/10.1016/j.eatbeh.2006.11.001 | eng |
| dcterms.references | Himmerich, H., Bentley, J., Lichtblau, N., Brennan, C., & Au, K. (2019). Facets of shared decision-making on drug treatment for adults with an eating disorder. In International Review of Psychiatry (Vol. 31, Issue 4, pp. 332–346). Taylor and Francis Ltd. https://doi.org/10.1080/09540261.2019.1571995 | eng |
| dcterms.references | Hinnouho, G. M., Singh-Manoux, A., Gueguen, A., Matta, J., Lemogne, C., Goldberg, M., Zins, M., & Czernichow, S. (2017). Metabolically healthy obesity and depressive symptoms: 16-year follow-up of the Gazel cohort study. PLoS ONE, 12(4). https://doi.org/10.1371/journal.pone.0174678 | eng |
| dcterms.references | Hod, R., Mohd Nor, N. H., & Maniam, S. (2022). Systematic review on e-cigarette and its effects on weight gain and adipocytes. In PloS one (Vol. 17, Issue 7, p. e0270818). NLM (Medline). https://doi.org/10.1371/journal.pone.0270818 | eng |
| dcterms.references | Iqbal, E., Govind, R., Romero, A., Dzahini, O., Broadbent, M., Stewart, R., Smith, T., Kim, C. H., Werbeloff, N., MacCabe, J. H., Dobson, R. J. B., & Ibrahim, Z. M. (2020). The side effect profile of Clozapine in real world data of three large mental health hospitals. PLoS ONE, 15(12 December). https://doi.org/10.1371/journal.pone.0243437 | eng |
| dcterms.references | Kahl, K., Lampen-Inkamp, S., Claassen, B., Peschel, T., & Schik, G. (2010). E.05.02 Metabolic alterations and their background in patients with affective disorders. European Neuropsychopharmacology, 20, S211. https://doi.org/10.1016/s0924-977x(10)70248-0 | eng |
| dcterms.references | Khalil, H., Ellwood, L., Lord, H., & Fernandez, R. (2020a). Pharmacological Treatment for Obesity in Adults: An Umbrella Review. In Annals of Pharmacotherapy (Vol. 54, Issue 7, pp. 691–705). SAGE Publications Inc. https://doi.org/10.1177/1060028019898912 | eng |
| dcterms.references | Khalil, H., Ellwood, L., Lord, H., & Fernandez, R. (2020b). Pharmacological Treatment for Obesity in Adults: An Umbrella Review. In Annals of Pharmacotherapy (Vol. 54, Issue 7, pp. 691–705). SAGE Publications Inc. https://doi.org/10.1177/1060028019898912 | eng |
| dcterms.references | Khuda, I. E., Nazish, S., Zeeshan, M. A., Shariff, E., Aljaafari, D., & Alabdali, M. (2022). It is illegal to post this copyrighted PDF on any website. Non-HDL Cholesterol, Obesity, and Metabolic Syndrome in Epileptic Patients. Primary Care Companion for CNS Disorders, 24(3), e1–e6. https://doi.org/10.4088/PCC.21m03057 | eng |
| dcterms.references | Kranzler, H. N., & Cohen, S. D. (2013). Psychopharmacologic Treatment of Psychosis in Children and Adolescents. Efficacy and Management. In Child and Adolescent Psychiatric Clinics of North America (Vol. 22, Issue 4, pp. 727–744). https://doi.org/10.1016/j.chc.2013.06.002 | eng |
| dcterms.references | Laaboub, N., Dubath, C., Ranjbar, S., Sibailly, G., Grosu, C., Piras, M., Délessert, D., Richard-Lepouriel, H., Ansermot, N., Crettol, S., Vandenberghe, F., Grandjean, C., Delacrétaz, A., Gamma, F., Plessen, K. J., von Gunten, A., Conus, P., & Eap, C. B. (2022). Insomnia disorders are associated with increased cardiometabolic disturbances and death risks from cardiovascular diseases in psychiatric patients treated with weight-gain-inducing psychotropic drugs: results from a Swiss cohort. BMC Psychiatry, 22(1). https://doi.org/10.1186/s12888-022-03983-3 | eng |
| dcterms.references | Lee, K., Abraham, S., & Cleaver, R. (2022a). A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. In General Hospital Psychiatry (Vol. 78, pp. 58–67). Elsevier Inc. https://doi.org/10.1016/j.genhosppsych.2022.07.006 | eng |
| dcterms.references | Lee, K., Abraham, S., & Cleaver, R. (2022b). A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. In General Hospital Psychiatry (Vol. 78, pp. 58–67). Elsevier Inc. https://doi.org/10.1016/j.genhosppsych.2022.07.006 | eng |
| dcterms.references | Liu, H. C., Yang, S. Y., Liao, Y. T., Chen, C. C., & Kuo, C. J. (2016a). Antipsychotic medications and risk of acute coronary syndrome in schizophrenia: A nested case-control study. PLoS ONE, 11(9). https://doi.org/10.1371/journal.pone.0163533 | eng |
| dcterms.references | Liu, H. C., Yang, S. Y., Liao, Y. T., Chen, C. C., & Kuo, C. J. (2016b). Antipsychotic medications and risk of acute coronary syndrome in schizophrenia: A nested case-control study. PLoS ONE, 11(9). https://doi.org/10.1371/journal.pone.0163533 | eng |
| dcterms.references | Liu, Y. K., Ling, S., Lui, L. M. W., Ceban, F., Vinberg, M., Kessing, L. V., Ho, R. C., Rhee, T. G., Gill, H., Cao, B., Mansur, R. B., Lee, Y., Rosenblat, J., Teopiz, K. M., & McIntyre, R. S. (2022). Prevalence of type 2 diabetes mellitus, impaired fasting glucose, general obesity, and abdominal obesity in patients with bipolar disorder: A systematic review and meta-analysis. In Journal of Affective Disorders (Vol. 300, pp. 449–461). Elsevier B.V. https://doi.org/10.1016/j.jad.2021.12.110 | eng |
| dcterms.references | Maremmani, A. G. I., Gazzarrini, D., Fiorin, A., Cingano, V., Bellio, G., Perugi, G., & Maremmani, I. (2018). Psychopathology of addiction: Can the SCL90-based five-dimensional structure differentiate Heroin Use Disorder from a non-substance-related addictive disorder such as Gambling Disorder? Annals of General Psychiatry, 17(1). https://doi.org/10.1186/s12991-018-0173-7 | eng |
| dcterms.references | Mejaddam, A., Krantz, E., Höskuldsdóttir, G., Fändriks, L., Mossberg, K., Eliasson, B., Trimpou, P., & Landin-Wilhelmsen, K. (2022). Comorbidity and quality of life in obesity–a comparative study with the general population in Gothenburg, Sweden. PLoS ONE, 17(10 October). https://doi.org/10.1371/journal.pone.0273553 | eng |
| dcterms.references | Moreira, F. P., Jansen, K., Cardoso, T. D. A., Mondin, T. C., Magalhães, P. v., Kapczinski, F., Souza, L. D. M., da Silva, R. A., Oses, J. P., & Wiener, C. D. (2019). Metabolic syndrome and psychiatric disorders: A population-based study. Revista Brasileira de Psiquiatria, 41(1), 38–43. https://doi.org/10.1590/1516-4446-2017-2328 | eng |
| dcterms.references | Morriss, R., Tyrer, F., Zaccardi, F., & Khunti, K. (2021). Safety of antidepressants in a primary care cohort of adults with obesity and depression. PLoS ONE, 16(1 January). https://doi.org/10.1371/journal.pone.0245722 | eng |
| dcterms.references | Núñez-Cortés, J. M., Mantilla Morató, T., Toro, R., Millán Pérez, J., Mangas Rojas, A., Ascaso, J., Civeira, F., Mostaza, J. M., Pintó, X., & Valdivielso, P. (2015). Metabolic syndrome in patients with clinical phenotype “hypertriglyceridemic waist.” Nutricion Hospitalaria, 32(3), 1145–1152. https://doi.org/10.3305/nh.2015.32.3.9138 | eng |
| dcterms.references | Orzelska-Górka, J., Mikulska, J., Wiszniewska, A., & Biała, G. (2022). New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression. In International Journal of Molecular Sciences (Vol. 23, Issue 18). MDPI. https://doi.org/10.3390/ijms231810624 | eng |
| dcterms.references | Oughli, H., Lenze, E. J., Locke, A. E., Yingling, M. D., Zhong, Y., Miller, J. P., Reynolds, C. F., Mulsant, B. H., Newcomer, J. W., Peterson, T. R., Müller, D. J., & Nicol, G. E. (2019). Getting to precision psychopharmacology: Combining clinical and genetic information to predict fat gain from aripiprazole. Journal of Psychiatric Research, 114, 67–74. https://doi.org/10.1016/j.jpsychires.2019.04.017 | eng |
| dcterms.references | Ozdemir, A. C., Wynn, G. M., Vester, A., Weitzmann, M. N., Neigh, G. N., Srinivasan, S., & Rudd, M. K. (2017). GNB3 overexpression causes obesity and metabolic syndrome. PLoS ONE, 12(12). https://doi.org/10.1371/journal.pone.0188763 | eng |
| dcterms.references | Pagán-Busigó, J. E., López-Carrasquillo, J., Appleyard, C. B., & Torres-Reverón, A. (2022). Beyond depression and anxiety; a systematic review about the role of corticotropin-releasing hormone antagonists in diseases of the pelvic and abdominal organs. PLoS ONE, 17(3 March). https://doi.org/10.1371/journal.pone.0264909 | eng |
| dcterms.references | Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., … Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. In The BMJ (Vol. 372). BMJ Publishing Group. https://doi.org/10.1136/bmj.n71 | eng |
| dcterms.references | Palacio-Ortiz, J. D., Londoño-Herrera, J. P., Nanclares-Márquez, A., Robledo-Rengifo, P., & Quintero-Cadavid, C. P. (2020). Psychiatric disorders in children and adolescents during the COVID-19 pandemic. In Revista Colombiana de Psiquiatria (Vol. 49, Issue 4, pp. 279–288). Elsevier Doyma. https://doi.org/10.1016/j.rcp.2020.05.006 | eng |
| dcterms.references | Pañero Herranz, C., & Madrid, A. M. (2021). FACULTAD DE CIENCIAS HUMANAS Y SOCIALES Obesidad y sobrepeso. Aspectos psicológicos, tratamiento y prevención | spa |
| dcterms.references | Panizzutti, B., Bortolasci, C. C., Spolding, B., Kidnapillai, S., Connor, T., Richardson, M. F., Truong, T. T. T., Liu, Z. S. J., Gray, L., Kim, J. H., Dean, O. M., Berk, M., & Walder, K. (2021). Biological mechanism(S) underpinning the association between antipsychotic drugs and weight gain. Journal of Clinical Medicine, 10(18). https://doi.org/10.3390/jcm10184095 | eng |
| dcterms.references | Párraga Martínez, I., López-Torres Hidalgo, J., del Campo Del Campo, J. M., Villena Ferrer, A., Morena Rayo, S., & Escobar Rabadán, F. (2014). Seguimiento de la adherencia al tratamiento antidepresivo en pacientes que inician su consumo. Atencion Primaria, 46(7), 357–366. https://doi.org/10.1016/j.aprim.2013.11.003 | spa |
| dcterms.references | Piña, I. L., di Palo, K. E., & Ventura, H. O. (2018). Psychopharmacology and Cardiovascular Disease. In Journal of the American College of Cardiology (Vol. 71, Issue 20, pp. 2346–2359). Elsevier USA. https://doi.org/10.1016/j.jacc.2018.03.458 | eng |
| dcterms.references | Pinzón, J. B., Serrano, N. C., & Díaz, L. A. (2007). Prevalencia Del Sindrome Metabolico. In Biomédica (Vol. 27). | spa |
| dcterms.references | Planansky, K. (1958). Changes in weight in patients receiving a “tranquilizing” drug. The Psychiatric Quarterly, 32(2), 289–303. https://doi.org/10.1007/BF01561635 | eng |
| dcterms.references | Pscheidt, S. L., Zardeto, H. N., de Sá Junior, A. R., & Schneider, I. J. C. (2022a). Cardiovascular diseases and use of antipsychotics in schizophrenia: a review. In Jornal Brasileiro de Psiquiatria (Vol. 71, Issue 3, pp. 253–272). Editora Cientifica Nacional Ltda. https://doi.org/10.1590/0047-2085000000376 | eng |
| dcterms.references | Pscheidt, S. L., Zardeto, H. N., de Sá Junior, A. R., & Schneider, I. J. C. (2022b). Cardiovascular diseases and use of antipsychotics in schizophrenia: a review. In Jornal Brasileiro de Psiquiatria (Vol. 71, Issue 3, pp. 253–272). Editora Cientifica Nacional Ltda. https://doi.org/10.1590/0047-2085000000376 | eng |
| dcterms.references | Rajjo, T., Mohammed, K., Alsawas, M., Ahmed, A. T., Farah, W., Asi, N., Almasri, J., Prokop, L. J., & Murad, M. H. (2017). Treatment of pediatric obesity: An umbrella systematic review. In Journal of Clinical Endocrinology and Metabolism (Vol. 102, Issue 3, pp. 763–775). Endocrine Society. https://doi.org/10.1210/jc.2016-2574 | eng |
| dcterms.references | Rakitin, A., Eglit, T., Kõks, S., Lember, M., & Haldre, S. (2014). Comparison of the metabolic syndrome risk in valproate-treated patients with epilepsy and the general population in Estonia. PLoS ONE, 9(7). https://doi.org/10.1371/journal.pone.0103856 | eng |
| dcterms.references | Rojas, E., Castro, A., Manzano, A., Suárez, M. K., Lameda, V., Carrasquero, R., Nava, M., & Bermúdez, V. (2021a). Diagnostic criteria and management of metabolic syndrome: Evolution overtime. In Gaceta Medica de Caracas (Vol. 128, Issue 4, pp. 480–504). Academia Nacional de Medicina. https://doi.org/10.47307/GMC.2020.128.4.5 | eng |
| dcterms.references | Rojas, E., Castro, A., Manzano, A., Suárez, M. K., Lameda, V., Carrasquero, R., Nava, M., & Bermúdez, V. (2021b). Diagnostic criteria and management of metabolic syndrome: Evolution overtime. In Gaceta Medica de Caracas (Vol. 128, Issue 4, pp. 480–504). Academia Nacional de Medicina. https://doi.org/10.47307/GMC.2020.128.4.5 | eng |
| dcterms.references | Schulz, P. (2019). Opportunities and challenges in psychopharmacology. In Dialogues in Clinical Neuroscience (Vol. 21, Issue 2, pp. 119–130). Les Laboratoires Seriver. https://doi.org/10.31887/DCNS.2019.21.2/pschulz | eng |
| dcterms.references | Simon, M. S., Barton, B. B., Glocker, C., & Musil, R. (2022). A comprehensive approach to predicting weight gain and therapy response in psychopharmacologically treated major depressed patients: A cohort study protocol. PLoS ONE, 17(7 July). https://doi.org/10.1371/journal.pone.0271793 | eng |
| dcterms.references | Siskind, D. J., Leung, J., Russell, A. W., Wysoczanski, D., & Kisely, S. (2016). Metformin for clozapine associated obesity: A systematic review and meta-analysis. PLoS ONE, 11(6). https://doi.org/10.1371/journal.pone.0156208 | eng |
| dcterms.references | Stancil, S. L., Abdel-Rahman, S., & Wagner, J. (2021). Developmental Considerations for the Use of Naltrexone in Children and Adolescents. Journal of Pediatric Pharmacology and Therapeutics, 26(7), 675–695. https://doi.org/10.5863/1551-6776-26.7.675 | eng |
| dcterms.references | Steffens, D. C., Wei Jiang, Krishnan, K. R. R., Karoly, E. D., Mitchell, M. W., O’Connor, C. M., & Kaddurah-Daouk, R. (2010). Metabolomic differences in heart failure patients with and without major depression. Journal of Geriatric Psychiatry and Neurology, 23(2), 138–146. https://doi.org/10.1177/0891988709358592 | eng |
| dcterms.references | Steuer, A. E., Schmidhauser, C., Tingelhoff, E. H., Schmid, Y., Rickli, A., Kraemer, T., & Liechti, M. E. (2016). Impact of cytochrome P450 2D6 function on the chiral blood plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its Phase I and II metabolites in humans. PLoS ONE, 11(3). https://doi.org/10.1371/journal.pone.0150955 | eng |
| dcterms.references | Suetani, R. J., Siskind, D., Reichhold, H., & Kisely, S. (2017). Genetic variants impacting metabolic outcomes among people on clozapine: a systematic review and meta-analysis. In Psychopharmacology (Vol. 234, Issue 20, pp. 2989–3008). Springer Verlag. https://doi.org/10.1007/s00213-017-4728-0 | eng |
| dcterms.references | Sugai, T., Suzuki, Y., Yamazaki, M., Shimoda, K., Mori, T., Ozeki, Y., Matsuda, H., Sugawara, N., Yasui-Furukori, N., Minami, Y., Okamoto, K., Sagae, T., & Someya, T. (2016). High prevalence of obesity, hypertension, hyperlipidemia, and diabetes mellitus in Japanese outpatients with schizophrenia: A nationwide survey. PLoS ONE, 11(11). https://doi.org/10.1371/journal.pone.0166429 | eng |
| dcterms.references | Tabatabaei-Malazy, O., Moghaddam, S. S., Rezaei, N., Sheidaei, A., Hajipour, M. J., Mahmoudi, N., Mahmoudi, Z., Dilmaghani-Marand, A., Rezaee, K., Sabooni, M., Razi, F., Kompani, F., Delavari, A., Larijani, B., & Farzadfar, F. (2021a). A nationwide study of metabolic syndrome prevalence in Iran; A comparative analysis of six definitions. PLoS ONE, 16(3 March). https://doi.org/10.1371/journal.pone.0241926 | eng |
| dcterms.references | Tabatabaei-Malazy, O., Moghaddam, S. S., Rezaei, N., Sheidaei, A., Hajipour, M. J., Mahmoudi, N., Mahmoudi, Z., Dilmaghani-Marand, A., Rezaee, K., Sabooni, M., Razi, F., Kompani, F., Delavari, A., Larijani, B., & Farzadfar, F. (2021b). A nationwide study of metabolic syndrome prevalence in Iran; A comparative analysis of six definitions. PLoS ONE, 16(3 March). https://doi.org/10.1371/journal.pone.0241926 | eng |
| dcterms.references | Taylor, J., Stubbs, B., Hewitt, C., Ajjan, R. A., Alderson, S. L., Gilbody, S., Holt, R. I. G., Hosali, P., Hughes, T., Kayalackakom, T., Kellar, I., Lewis, H., Mahmoodi, N., McDermid, K., Smith, R. D., Wright, J. M., & Siddiqi, N. (2017). The effectiveness of pharmacological and non-pharmacological interventions for improving glycaemic control in adults with severe mental illness: A systematic review and meta-analysis. PLoS ONE, 12(1). https://doi.org/10.1371/journal.pone.0168549 | eng |
| dcterms.references | Tubbs, A. S., Khader, W., Fernandez, F., & Grandner, M. A. (2020). The common denominators of sleep, obesity, and psychopathology. In Current Opinion in Psychology (Vol. 34, pp. 84–88). Elsevier B.V. https://doi.org/10.1016/j.copsyc.2019.11.003 | eng |
| dcterms.references | Ulrich, S., Ricken, R., & Adli, M. (2017a). Tranylcypromine in mind (Part I): Review of pharmacology. In European Neuropsychopharmacology (Vol. 27, Issue 8, pp. 697–713). Elsevier B.V. https://doi.org/10.1016/j.euroneuro.2017.05.007 | eng |
| dcterms.references | Ulrich, S., Ricken, R., & Adli, M. (2017b). Tranylcypromine in mind (Part I): Review of pharmacology. In European Neuropsychopharmacology (Vol. 27, Issue 8, pp. 697–713). Elsevier B.V. https://doi.org/10.1016/j.euroneuro.2017.05.007 | eng |
| dcterms.references | Ulrich, S., Ricken, R., & Adli, M. (2017c). Tranylcypromine in mind (Part I): Review of pharmacology. In European Neuropsychopharmacology (Vol. 27, Issue 8, pp. 697–713). Elsevier B.V. https://doi.org/10.1016/j.euroneuro.2017.05.007 | eng |
| dcterms.references | van Mil, E. G. A. H., Westerterp, K. R., Kester, A. D. M., Delemarre-van De Waal, H. A., Gerver, W. J. M., & Saris, W. H. M. (2007). The effect of sibutramine on energy expenditure and body composition in obese adolescents. Journal of Clinical Endocrinology and Metabolism, 92(4), 1409–1414. https://doi.org/10.1210/jc.2006-0264 | eng |
| dcterms.references | Vasudev, K., Choi, Y. H., Norman, R., Kim, R. B., & Schwarz, U. I. (2017). Genetic Determinants of Clozapine-Induced Metabolic Side Effects. In Canadian Journal of Psychiatry (Vol. 62, Issue 2, pp. 138–149). SAGE Publications Inc. https://doi.org/10.1177/0706743716670128 | eng |
| dcterms.references | Vázquez-Bourgon, J., Gómez-Revuelta, M., Mayoral-van Son, J., Labad, J., Ortiz-García de la Foz, V., Setién-Suero, E., Ayesa-Arriola, R., Tordesillas-Gutiérrez, D., Juncal-Ruiz, M., & Crespo-Facorro, B. (2022). Pattern of long-term weight and metabolic changes after a first episode of psychosis: Results from a 10-year prospective follow-up of the PAFIP program for early intervention in psychosis cohort. European Psychiatry, 65(1). https://doi.org/10.1192/j.eurpsy.2022.2308 | eng |
| dcterms.references | Vázquez-Bourgon, J., Ibáñez Alario, M., Mayoral-van Son, J., Gómez Revuelta, M., Ayesa Arriola, R., Juncal Ruiz, M., Ortiz-García de la Foz, V., & Crespo Facorro, B. (2020). A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients. European Neuropsychopharmacology, 39, 46–55. https://doi.org/10.1016/j.euroneuro.2020.08.009 | eng |
| dcterms.references | Vogel Martinez, M. I., León, F., Torres, R., & Crossley, N. A. (2017). Antipsicóticos de primera y segunda generación en esquizofrenia: eficacia, efectividad y efecto de la dosis utilizada. ARS MEDICA Revista de Ciencias Médicas, 42(1). https://doi.org/10.11565/arsmed.v42i1.452 | spa |
| dcterms.references | Voith, V. L. (1993). Recent advances in psychopharmacology. Tijdschrift Voor Diergeneeskunde, 118 Suppl 1. https://doi.org/10.1016/j.ypsc.2022.03.009 | eng |
| dcterms.references | Wang, H. H., Lee, D. K., Liu, M., Portincasa, P., & Wang, D. Q. H. (2020). Novel insights into the pathogenesis and management of the metabolic syndrome. Pediatric Gastroenterology, Hepatology and Nutrition, 23(3). https://doi.org/10.5223/PGHN.2020.23.3.189 | eng |
| dcterms.references | Wolff, J., Reißner, P., Hefner, G., Normann, C., Kaier, K., Binder, H., Hiemke, C., Toto, S., Domschke, K., Marschollek, M., & Klimke, A. (2021). Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders. PLoS ONE, 16(7 July). https://doi.org/10.1371/journal.pone.0255192 | eng |
| dcterms.references | Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001). Global and societal implications of the diabetes epidemic. In Nature (Vol. 414, Issue 6865, pp. 782–787). https://doi.org/10.1038/414782a | eng |
| oaire.version | info:eu-repo/semantics/acceptedVersion | spa |
| sb.programa | Maestría en Psicología | spa |
| sb.sede | Sede Cúcuta | spa |